Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Current Deferred Revenue (2016 - 2025)

Editas Medicine (EDIT) has disclosed Current Deferred Revenue for 11 consecutive years, with $54.2 million as the latest value for Q2 2025.

  • Quarterly Current Deferred Revenue rose 269.14% to $54.2 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $54.2 million through Jun 2025, up 269.14% year-over-year, with the annual reading at $60.4 million for FY2024, 635.01% up from the prior year.
  • Current Deferred Revenue for Q2 2025 was $54.2 million at Editas Medicine, up from $2.0 million in the prior quarter.
  • The five-year high for Current Deferred Revenue was $68.9 million in Q4 2022, with the low at $2.0 million in Q1 2025.
  • Average Current Deferred Revenue over 5 years is $27.8 million, with a median of $14.7 million recorded in 2024.
  • The sharpest move saw Current Deferred Revenue plummeted 88.07% in 2023, then skyrocketed 737.95% in 2024.
  • Over 5 years, Current Deferred Revenue stood at $11.3 million in 2021, then soared by 507.85% to $68.9 million in 2022, then crashed by 88.07% to $8.2 million in 2023, then surged by 635.01% to $60.4 million in 2024, then decreased by 10.3% to $54.2 million in 2025.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $54.2 million, $2.0 million, and $60.4 million for Q2 2025, Q1 2025, and Q4 2024 respectively.